Antiplatelet dilemma: Clopidogrel or aspirin for long-term cardiovascular protection after dual antiplatelet therapy following PCI.

[ 4 ] The CAPRIE trial demonstrated that clopidogrel exhibited a marginally significant benefit over aspirin in preventing stroke, MI, and vascular disease among 19,185 patients with a recent stroke, MI, or peripheral artery disease (annual event rate 5.32% vs 5.83%; P = .043).

also in 8,164 other papers

Despite clopidogrel’s superior efficacy and favorable safety profile, aspirin remains recommended due to its marginally statistically significant inferiority and cost-effectiveness; approximately 200 patients must use clopidogrel instead of aspirin for 1 year to prevent a single vascular event.

also in 358 other papers